Register for the Somatuline® Depot
Acromegaly Answers Webinar Series
Register to learn more about acromegaly,
its impact, and available treatment options
If you know others who might benefit from the Somatuline® Depot Acromegaly Answers Webinar Series, please tell them to register and participate.
When you have completed the brief form, simply click "Submit" to complete your registration.
* Required field
By clicking Submit, you agree to receive a user name and password to attend the webinar series and receive reminders and information about the Acromegaly Answers Webinar Series.
If you check the Somatuline® Depot box, before clicking submit, you agree to receive future communication about Somatuline® Depot, such as emails, coupons, and other helpful tools!
Tercica, Inc. respects the privacy of visitors to its Web sites, and we recognize your need for appropriate protection and management of personally identifiable information you share with us (i.e., name, address, and telephone number). To read the Privacy Policy, click here.
Important Indication and Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline® Depot (lanreotide) Injection 60mg.
There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.
Please see Full Prescribing Information for additional important information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Privacy Policy | Terms & Conditions | SomatulineDepot.com